Dr. Carleone is the Non-Executive Chairman of Avid Bioservices, Inc., a biopharmaceutical manufacturing company focused on mammalian cell technology to support the pharmaceutical industry (since 2017). Dr. Carleone is also Senior Advisor for OES Europe, an independent advisory network specializing in strategic cross-border mergers & acquisitions and in management buy-outs (since 2018). Dr. Carleone previously served as Chairman of the Board of AMPAC Fine Chemicals LLC (from 2015 to 2018), a leading manufacturer of pharmaceutical active ingredients. Dr. Carleone was also President and Chief Executive Officer of American Pacific Corporation (from 2010 to 2015), a leading custom manufacturer of fine and specialty chemicals and propulsion products, and a director of American Pacific Corporation (from 2006 to 2015). Dr. Carleone also served as Chairman of the Board of American Pacific Corporation from March 12, 2013, until it was acquired by H.I.G. Capital, LLC, on February 27, 2014, and President and Chief Operating Officer of American Pacific Corporation from 2006 to 2009.

Dr. Carleone received his bachelor’s degree in Mechanical Engineering from Drexel University, Philadelphia, Pennsylvania, in 1968; his masters’ degree in Applied Mechanics from Drexel University in 1970; and his doctorate degree in Applied Mechanics from Drexel University in 1972.


Dr. Ferruzzi is the Director of the Arkansas Children’s Nutrition Center and Professor and Chief, Section of Developmental Nutrition in the Department of Pediatrics at the University of Arkansas for Medical Sciences (since 2021). Dr. Ferruzzi also serves as Endowed Chair in Digestive Disease & Nutrition Research at Arkansas Children’s Research Institute (since 2022).  Previously, Dr. Ferruzzi was a David H. Murdock Distinguished Professor from 2019 to 2021 and a Professor of Food Science and Nutrition in the Plants for Human Health Institute and the Department of Food, Bioprocessing and Nutrition Science at North Carolina State University from 2016 to 2019. Dr. Ferruzzi was also a Professor in the Department of Food Science at Purdue University from 2004 to 2016, a Research Scientist in the Coffee and Tea Beverage Development group at Nestlé Research & Development Center, Marysville, Ohio, and a Research Scientist at the Nutrition & Health and Scientific & Nutritional Support Departments at the Nestlé Research Centre in Lausanne, Switzerland. He received his B.S. in Chemistry from Duke University and his M.S. and Ph.D. in Food Science and Nutrition from The Ohio State University.

Dr. Ferruzzi is recognized for his expertise in analytical chemistry and its applications to food and nutrition research and product development. Dr. Ferruzzi’s research has been consistently funded by federal agencies including the U.S. Department of Agriculture, the National Institutes of Health, and the United States Agency for International Development, as well as the food industry. His core activities in food chemistry, food processing, and translational nutrition have resulted in over 208 publications as well as extensive national and international collaborations, research, and product development.

For his research efforts Dr. Ferruzzi has received awards from the Institute of Food Technologists (2010 Samuel Cate Prescott Young Investigator Award), the American Society for Nutrition (2011 Mary Rose Swartz Young Investigator Award), Purdue University (2012 Agricultural Research Award), the General Mills Bell Institute of Health and Nutrition (2018 Innovation Award), and IFT/ASN (2019 Gilbert A. Leveille Award and Lectureship). Dr. Ferruzzi was also named a University Faculty Scholar by Purdue University in 2013.

Dr. Ferruzzi is a member of the Board of Trustees for the North America branch of the International Life Science Institute. He is also a professional member of the Institute of Food Technologist (IFT), the American Society for Nutrition (ASN), the American Chemical Society (ACS), and a Fellow of the Royal Society of Chemistry. Dr. Ferruzzi has held multiple leadership roles in these societies, most notably IFT and ASN at both local and national levels. He served as Chair of the Food Science & Nutrition Solutions Taskforce, a joint working group between IFT-ASN-IFIC and the Academy of Nutrition and Dietetics (AND). Additionally, Dr. Ferruzzi serves on the editorial boards of Nutrition Research, Nutrition Today, Critical Reviews in Food Science and Nutrition, and as Associate Editor for the Royal Society of Chemistry’s journal Food & Function.


Ms. Jackson is the former Chairman, President, and Chief Executive Officer of HarbisonWalker International (from 2017 to 2023), the largest supplier of ceramic refractories in the U.S. with operations in the U.S., Mexico, Europe, and Southeast Asia and commercial interests globally. She previously served as Corporate Officer, Senior Vice President, and General Manager at HarbisonWalker from 2014 to 2017. Since 2021, Ms. Jackson has served on the board of directors of AZZ Inc., a publicly-traded provider of hot-dip galvanizing and coil coating solutions to a broad range of end-markets, predominantly in North America.

Prior to joining HarbisonWalker in 2014, Ms. Jackson held a number of senior corporate and management roles at Carpenter Technology Corporation (2011-13), a global leader in the development, manufacture, and distribution of cast/wrought and powder metal stainless steels and specialty alloys, and PPG Industries (1999-2011), a global supplier of paints, chemicals, optical and specialty products, and glass. Ms. Jackson holds a B.S. in Business Administration from Duquesne University, an MBA from Carnegie Mellon University, and a Juris Doctorate from the University of Pittsburgh.

Ms. Jackson is a licensed attorney. Since 2014, she has been a Director and Member of the Governance Committee of Junior Achievement of Western Pennsylvania.


Mr. Jain has more than 33 years of experience providing audit and audit-related services to large global companies with the international accounting firm PricewaterhouseCoopers (he retired from the firm in 2020). His experience includes service as the Global and US Automotive Assurance Sector Leader from 2012 until 2015, and service as a senior partner in the firm’s Governance Insights Center from 2018 until 2020. He also led the firm’s Consumer and Industrial Products Assurance teams in Detroit and Chicago and served on the firm’s Global Auditing Committee, which oversees the quality and consistency of the firm’s global audit methodology and tools.

Mr. Jain is a Certified Public Accountant, recipient of the Elijah Watt Sells Award, and was trained as a Chartered Accountant in the UK before moving to the USA with PricewaterhouseCoopers. Mr. Jain has significant global experience, including mature and emerging markets.


Dr. Landry is the Hamilton Southworth Professor of Medicine, Columbia University / NewYork-Presbyterian and has been a member of the faculty of Columbia University since 1985. He also serves as the Director of the Division of Experimental Therapeutics and Physician-in-Chief for the Medical Service at NewYork-Presbyterian Hospital/Columbia Medical Center. He previously served as the Samuel Bard Professor and Chair of the Department of Medicine at Columbia University’s College of Physicians and Surgeons from 2008 to 2023. At Columbia, Dr. Landry developed the first artificial enzyme to degrade cocaine and his report in Science was voted one of the top 25 papers in the world for 1993 by the American Chemical Society. His discovery that vasopressin can be used to treat vasodilatory shock fundamentally changed intensive care medicine. He also pioneered an embryo-sparing approach to the generation of human embryonic stem cells.

Dr. Landry previously was a Director of Tonix Pharmaceuticals Holding Corp. from 2011 to 2019, which is a publicly-traded pharmaceutical company that develops next-generation medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache.

Dr. Landry was a co-founder of Tegrigen Therapeutics, LLC, a private company that developed novel therapeutics for inflammation, fibrosis, thrombosis, autoimmunity, and cancer based on pure orthosteric antagonists to specific integrins. Dr. Landry was also a co-founder of Vela Pharmaceuticals, which developed several drugs for central nervous system disorders, including very low dose (VLD)-cyclobenzaprine for fibromyalgia syndrome. Dr. Landry also co-founded Omnitia Therapeutics Inc., which developed novel therapeutics for neurodegenerative diseases based on small molecule antagonists to stress granule formation.

Dr. Landry is a leader in the ethical development of embryonic stem cells and served as a member of the President’s Council on Bioethics during the George W. Bush administration. In 2008, Dr. Landry was awarded the Presidential Citizens Medal, the nation’s second-highest civilian award.

Dr. Landry graduated from Lafayette College, completed his Ph.D. in organic chemistry under Nobel laureate R.B. Woodward at Harvard University in 1979 and then obtained his M.D. degree from Columbia University’s College of Physicians and Surgeons in 1983. Dr. Landry has published 116 peer-reviewed articles, authored 33 review articles or book chapters, and was awarded 51 patents as inventor or co-inventor.

Mr. Paul Manning has been Sensient’s Chairman, President and Chief Executive Officer since April 21, 2016. He joined the Company in 2009 as General Manager, Food Colors North America, and became President of the Color Group in 2010. He became President and Chief Operating Officer of the Company in October 2012, and President and Chief Executive Officer in February 2014. Before joining the Company, he worked for Danaher Corporation as Mergers and Acquisitions Integration Manager of the Fluke Division and he held various supply chain and project manager positions with McMaster-Carr Supply Company. He holds a B.S. degree in Chemistry from Stanford University and an MBA from Northwestern University. He attended Stanford University on a Naval ROTC scholarship and served in the U.S. Navy as a Surface Warfare Officer for four years.

During his four years of working within and then running the Color Group, Mr. Manning gained a thorough understanding of both the opportunities and the challenges facing the Company’s Color businesses and made critical contributions to its improved performance. As the Company’s President and Chief Operating Officer, his management skills and experience allowed him to make similar contributions in the Company’s other businesses, including his critical role in the relocation of the Flavors & Extracts Group headquarters from Indianapolis to the Chicago area on time and on budget. In his current position as the Company’s Chairman, President and Chief Executive Officer, he has been responsible for the continued success of the Company, including its strong profits and sales, upgrading of sales force and general manager talent, leading the Board of Directors, and articulating and executing the Company’s strategy.

Ms. McKeithan-Gebhardt is Manager of Troika Ventures, LLC (since 2021), a private limited liability company engaged in the management, purchase, and sale of oil and gas overriding royalty and royalty interests. She was previously the Chief Executive Officer, President, and Chief Operating Officer of Tamarack Petroleum Company, Inc. (from 2019 to 2021), and the Chief Executive Officer of Tamarack River Resources, LLC (from 2009 to 2021). She also previously served as President and Chief Operating Officer of Tamarack Petroleum Company, Inc. (from 2009 to 2019) and Vice President and General Counsel of Tamarack Petroleum Company, Inc. (from 1991 to 2009). Tamarack Petroleum Company, Inc. is a private company engaged in oil and gas exploration. Tamarack River Resources, LLC is a Delaware limited liability company of which Tamarack Petroleum Company, Inc., is the majority member. Prior to joining Tamarack Petroleum, Ms. McKeithan-Gebhardt was an attorney in private practice.

As a former Chief Executive Officer, President, and Chief Operating Officer, and also previously as Vice President and General Counsel, Ms. McKeithan-Gebhardt had primary responsibility for, and extensive experience in, a range of strategic and operational matters, including human resources, compensation and employee benefits, financial management, strategic planning, regulatory and compliance, legal affairs, and risk management.

Ms. McKeithan-Gebhardt earned a bachelor of arts degree in Business Administration from Cardinal Stritch University in 1980 and a Juris Doctorate degree summa cum laude from Marquette University Law School in 1987. Ms. McKeithan-Gebhardt currently serves as a member of the Marquette University Law School Advisory Board.

Mr. Morrison is Executive Vice President and Chief Financial Officer of Ball Corporation (since 2021), a leading global supplier of innovative, sustainable packaging solutions for beverage, food, and household products customers. He previously served as Senior Vice President and Chief Financial Officer (from 2010 to 2021) as well as Vice President and Treasurer of Ball Corporation (from 2000 to 2010). Prior to joining Ball Corporation, Mr. Morrison held senior corporate banking roles at Bank One, First Chicago, and NBD Bank, Detroit.

Mr. Morrison is an Executive Committee Member of the Board for the National Association of Manufacturers and previously was the Community Chairman of the Denver Chapter of the Kelley School of Business Indiana University. He also previously served as Chairman of the National Association of Corporate Treasurers and as an expert testimony witness to the U.S. House of Representatives Agricultural Committee on Dodd Frank legislation. Mr. Morrison has been recognized as CFO of the Year by CFO Magazine and Institutional Investor.

Mr. Morrison received his Bachelor’s Degree (1984) in Finance from Indiana University and his M.B.A. (1988) from Wayne State University.

Ms. Whitelaw served as Senior Vice President of Operations of Wisconsin Physician Services, a provider of health insurance and benefit plan administration, from 2001 until her retirement in 2010, where she was responsible for managing more than 430 employees. Before that, Ms. Whitelaw served more than 15 years in various executive positions, including as President and Chief Operating Officer (1992 to 1997) and Vice President of National Business Development at Blue Cross Blue Shield of Wisconsin, a comprehensive health and dental insurer. Among other things, while at Blue Cross Blue Shield, Ms. Whitelaw was responsible for managing insurance risk underwriting activities, regulatory compliance, and the development and implementation of appropriate sales incentive programs. Prior to its merger into another public utility in 2000, Ms. Whitelaw served on the board and on the audit, nominating, and retirement plan investment committees of WICOR Corporation, a Wisconsin energy utility.

Ms. Whitelaw is active in the local Wisconsin community. She currently serves on the board of Network Health, a Wisconsin based private health insurer, the Kingdom Prep Lutheran School, and the board of the Wisconsin Women’s Health Foundation, a nonprofit organization dedicated to improving the health and lives of women and their families through education, outreach programs, and partnerships. Ms. Whitelaw’s prior board service includes Milwaukee Public Museum, Goodwill Industries, United Way of Greater Milwaukee, Blue Cross Blue Shield Foundation, Metropolitan Milwaukee Association of Commerce, Greater Milwaukee Committee, and Bradley Center Sports and Entertainment Corporation.